News article

The latest from the DPC awards HQ
5
Nov

Winners crowned at 2019 DPC Industry Awards

Pioneers and innovators were celebrated at the second annual DPC Industry Awards.

Captains of industry were rewarded for efforts to improve care for people with diabetes, with 18 trophies handed out.

The Diabetes Professional Care (DPC) Industry Awards in association with the Diabetes Times celebrated achievements, standards of excellence and commitment to quality and positive outcomes led by companies working in our community.

The ceremony took place on the evening of day one of the 2019 DPC conference, which took place on Tuesday 29 and Wednesday 30 October at Olympia London.

DPC founder Maggie Meer said: “Congratulations to all the companies and organisations, the awards are testament to their hard work, dedication, innovation and, more importantly, the life-changing difference they are making to people with diabetes.

“We launched the awards to recognise the crucial role played by industry in developing and providing products, services and research that enable people with diabetes to have better outcomes.”

Oliver Jelley, Editor of the Diabetes Times, said: “These awards are about celebrating the achievements, standards of excellence and commitment to quality and positive outcomes of the companies working in diabetes care. We were proud to be part of this positive initiative and congratulate all the winners for going above and beyond to improve diabetes care.”

Entries were judged independently by leading professionals from the diabetes community, including chair of the Association of British Clinical Diabetologists (ABCD) and Consultant in Diabetes and Endocrinology Dr Dinesh Nagi and Abigail Kitt, who is Quality Improvement Lead (Diabetes), NHS England – South East Clinical Networks.

The judges also included Professor Ketan Dhatariya, Chair of the Joint British Diabetes Societies Inpatient Group (JBDS), Dr David Lipscomb, Consultant Endocrinologist, Sussex Community Foundation NHS Trust, and Consultant Physician at Northampton General Hospital NHS Trust, Dr Anne Kilvert, University of Leicester researcher, Dr Charles Fox and Professor Alan Sinclair, Director of the Foundation for Diabetes Research in Older People (FDROP).

Medical Education Campaign of the Year
WINNER: Sanofi

Hypo Awareness Week, a seven-day national campaign to raise awareness about and reduce episodes of hypoglycaemia, has been taking place annually during the first week of October since 2012.

This year’s record-breaking campaign saw healthcare professionals from 633 sites – up from 549 – sign-up to raise awareness of hypoglaecamia, as part of a national drive to improve staff knowledge and patient care.

Since it began the prevalence of all hypoglycaemic episodes in hospital has decreased from 26 per cent in 2011 to 18 per cent in 2017, according to the 2017 National Diabetes Inpatient Audit report.

HCP Education Programme of the Year
WINNER: EDEN

Effective Diabetes Education Now! (EDEN) was established in 2012 as a wide scale transformation programme addressing the skill gaps and changing models of care in diabetes knowledge in healthcare professionals.

The team, made up of specialists in education, clinical and academic roles, provide organisations with the opportunity to transform diabetes care by enhancing the skill levels of staff involved in diabetes treatment.

Their knowledge and experience has proven to be an invaluable help to many pharmacists new to clinical practice. By delivering effective care and education for people with diabetes, their ultimate aim is to help people living with diabetes to have a better quality of life.

People Education Programme of the Year
WINNER: Abbott Diabetes Care

Abbott is a global leader in developing, manufacturing and marketing glucose monitoring systems designed to help people better manage their diabetes.

Their webinar programme was developed in collaboration with healthcare professionals to maximise the utility of the FreeStyle Libre system and is being used by both patients and Healthcare professionals to help increase knowledge and understanding of the system.

In six months they have educated nearly 7,000 patients and 500 HCPs spanning a variety of topics to help people both manage their diabetes more efficiently every day and using our product to the best of its capability.

Innovation Award
WINNER: Healthy.io

Healthy.io are the category creators of smartphone urinalysis who offer the only FDA-cleared and CE-approved home urine test equivalent to lab-based devices.

Healthy.io’s technology and innovation have great potential to improve diabetes patient outcomes by increasing adherence and compliance to critical diabetes care processes. Interventions like this can also reduce costs and release valuable clinical time to spend with patients, making it a win-win for everyone.

Winning this award will help validate and support their efforts of expanding their project across the NHS, as well as extending its technology to a range of different pathways.

Their multidisciplinary team specialises in computer vision, product design, and clinical practice. They balance cutting-edge technology, superior user centric design and regulatory knowledge to bring clinical innovation from the lab to the home.

Marketing Campaign of the Year
WINNER: Sanofi

Hypo Awareness Week has been taking place annually since 2012. During this period the prevalence of all hypoglycaemic episodes in hospital has decreased from 26 per cent in 2011 to 18 per cent in 2017, according to the 2017 National Diabetes Inpatient Audit report.

The campaign improves standards in healthcare and helps save lives.

Hypo Awareness Week, a seven-day national campaign to raise awareness about and reduce episodes of hypoglycaemia, has been taking place annually during the first week of October since 2012.

This year’s record-breaking campaign saw healthcare professionals from 633 sites – up from 549 – sign-up to raise awareness of hypoglaecamia, as part of a national drive to improve staff knowledge and patient care.

Since it began the prevalence of all hypoglycaemic episodes in hospital has decreased from 26 per cent in 2011 to 18 per cent in 2017, according to the 2017 National Diabetes Inpatient Audit report.

Digital Health Initiative of the Year
WINNER: OurPath

OurPath was the first online programme used by the NHS to help with long-term behaviour change. By providing support from a personal nutritionist or dietician OurPath support people at risk of developing, and living, with type 2 diabetes to self-manage their condition as well as help those who wish to make health lifestyle changes.

In 2017, just 12-months after launching, OurPath became the first ever online behavioural change programme to be commissioned by the NHS.

Recognised as one of the Top 50 start-ups in the EU, OurPath has been adopted across more than 50 CCGs in partnership with the NHS.

OurPath goes a step beyond the state-of-the-art, by building artificial intelligence, machine learning and remote services into its core product and combining them with personal support from a dietitian or nutritionist, as well as a thriving community.

Type 2 Diabetes Prevention Award
WINNER: Leicester Diabetes Centre

The Leicester Diabetes Centre continues to lead the way in diabetes research. Leicester was the first UK city to join the global programme, making the world notice how seriously the city and the UK is taking the diabetes epidemic. 

The team has worked tirelessly in partnership with other stakeholders to engage with different at-risk communities using creative and dynamic ideas – such as Walking Cricket, Healthy Goals and various screening events.

There is still work to do, but the team are committed to driving down type 2 diabetes rates across the city and the rest of the world.

Healthy Living Initiative of the Year
WINNER: OurPath

OurPath was the first online programme used by the NHS to help with long-term behaviour change. By providing support from a personal nutritionist or dietician OurPath support people at risk of developing, and living, with type 2 diabetes to self-manage their condition as well as help those who wish to make health lifestyle changes.

In 2017, just 12-months after launching, OurPath became the first ever online behavioural change programme to be commissioned by the NHS.

Recognised as one of the Top 50 start-ups in the EU, OurPath has been adopted across more than 50 CCGs in partnership with the NHS.

OurPath goes a step beyond the state-of-the-art, by building artificial intelligence, machine learning and remote services into its core product and combining them with personal support from a dietitian or nutritionist, as well as a thriving community.

Research Project of the Year
WINNER: Leicester Diabetes Centre

The Leicester Diabetes Centre continues to lead the way in diabetes research. Leicester was the first UK city to join the global programme, making the world notice how seriously the city and the UK is taking the diabetes epidemic.

The Leicester Changing Diabetes programme has introduced a number of initiatives to increase awareness and encourage people across the city to take better care of their health, but also provided evaluation expertise to assess existing initiatives with the aim of improving them.

The team has worked tirelessly in partnership with other stakeholders to engage with different at-risk communities using creative and dynamic ideas – such as Walking Cricket, Healthy Goals and various screening events.

Product of the Year
WINNER: Roche Diabetes Care 

Roche Diabetes Care has been a pioneer in providing innovation in diabetes technology and services for more than 40 years, helping people with diabetes to live their lives as actively as possible.

As a leader in the diabetes care space, with vast experience across glucose monitoring and pump therapy, they are excited to offer innovation in the world’s first insulin micropump, Accu-Chek Solo.

The patient feedback from this pilot has been excellent, and following the success of this initial stage, the Accu-Chek Solo could now help a further 400,000 people, including 29,000 children, living with type 1 diabetes in the UK spend more time in range with minimal impact on their day-to-day life when the product launches in 2020.

HIGHLY COMMENDED: AstraZeneca

AstraZeneca is a UK research and development pharmaceutical company with 6500 employees in the UK. AZ supplies 42 different medicines to UK patients and has a heritage is developing innovative medicines across different disease areas including diabetes.

A UK sales, marketing and medical team consisting of approximately 150 individuals supporting the AstraZeneca diabetes portfolio Forxiga, launched in the UK in 2012, was the first in class SGLT2 inhibitor to market for the treatment of type 2 diabetes.

In November 2018, AZ reported cardiovascular outcomes with Forxiga in the largest cardiovascular outcomes study to date. This data expanded the understanding of the benefits this class of medications can have in improving outcomes for patients, especially those patients at lower risk or no established cardiovascular disease.

In March 2019, following the read out of two phase 3 trials, Forxiga became the first licensed adjunct therapy to insulin for adult patients with type 1 diabetes.

Most recently, Forxiga is the first SGLT-2 to have been able to demonstrate cardiovascular benefits in a group of patients both with and without T2D. These exciting new findings offer clinically meaningful insights into the potential of the medicine to reduce the burden of heart failure in patients with and without type 2 diabetes.

Most Influential Diabetes Technology Company of the Year
WINNER: Abbott Diabetes Care 

Abbott’s diabetes care division in the UK has continued to support the most innovative monitoring device launched in the field of diabetes in some time with novel programmes and initiatives, supporting both Healthcare Professionals and patients alike.

Alongside the FreeStyle Libre system, our campaigns have aimed to break a stereotype as to how marketing is delivered in a healthcare environment. The disruption the FreeStyle Libre system has had on the glucose monitoring market has influenced not just the NHS, but other legal bodies like the DVLA, securing people with diabetes access to the best technology to help them improve their diabetes management.

Industry Collaboration of the Year
WINNER: EDEN

Effective Diabetes Education Now! (EDEN) was established in 2012 as a wide scale transformation programme addressing the skill gaps and changing models of care in diabetes knowledge in Health Care Professionals.

Eden Training (Effective Diabetes Education Now) is highly regarded by HCPs and has proven that good quality education improves outcomes for patients.

Eden furthered their ongoing collaborative partnerships with the pharmaceutical industry throughout 2018, based upon the organisation’s many years of success in diabetes.

In early 2018, insight from the regional commercial teams highlighted gaps in HCPs knowledge in how to treat people living with diabetes. Whilst there were areas of good practice there was inequality of care across Local Health Economies and a growing lack of consistency.

It was agreed that the best way for the company to support HCPs and improve patient care was to support specific, local training.

Diabetes Charity of the Year
WINNER: X-PERT HEALTH

X-PERT HEALTH is a small team of 12 individuals working hard for a registered charity that keeps abreast with the latest evidence base for diabetes prevention and management.

Each year 100-200 educators deliver NICE compliant structured education to patients and enable around 60,000 people with prediabetes, type 2 diabetes and type 1 diabetes to develop the knowledge, understanding and confidence to self-manage their condition.

This results in a proven track record to impact positively on peoples’ lives by substantially improving health and wellbeing, reducing risk of diabetes-related complications and saving NHS costs.

HIGHLY COMMENDED: Dopps International

The DIABETES OUTREACH PREVENTION PROGRAMMES (DOPPS) is dedicated to providing education on prevention, early diagnosis and access to treatment for diabetes in the UK and worldwide, especially those who are living in low-income areas.

Their primary aim is to help people living with diabetes to have a better understanding of their condition and provide support to help people to live with diabetes.

In their own time the dedicated team hold diabetes prevention days for the public in order to promote awareness and help people to delay or prevent diabetes.

We have helped many people who never knew they had developed diabetes to seek the appropriate help and those with pre- diabetes to change their lifestyle in order to them prevent developing diabetes.

Medical Device Company of the Year
WINNER: Insulet

Headquartered in Massachusetts, USA, Insulet is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform.

Insulet has a new, experienced and ambitious team who are committed to supporting the type 1 diabetes community in the UK. Their goal is to enable more people with type 1 diabetes experience the quality of lifeand glycaemic benefits that insulin pumps can bring and ensure that they have an insulin pump choice to meet their individual needs.

Pioneer of the Year
WINNER: GlucoRx

GlucoRx has saved the NHS £100m by introducing high-quality products at cheaper prices. Group Managing Director, Chris Chapman, has ploughed some of the profits into supporting the local community and has also set up a health centre in Tanzania.

Chris Chapman had type 2 diabetes and reversed it.  His own experiences means he empathises with people with who have it. Through his work and commitment, he has saved the NHS £100m and improved thousands of lives in the UK and Africa. He cares about what he does and has set up football teams to encourage young people in deprived areas to become active.

Diabetes Times Excellence Award
WINNER: AstraZeneca

AstraZeneca is a UK research and development pharmaceutical company with 6,500 employees in the UK. AZ supplies 42 different medicines to UK patients and has a heritage is developing innovative medicines across different disease areas including diabetes.

A UK sales, marketing and medical team consisting of approximately 150 individuals supporting the AstraZeneca diabetes portfolio Forxiga, launched in the UK in 2012, was the first in class SGLT2 inhibitor to market for the treatment of type 2 diabetes.

In November 2018, AZ reported cardiovascular outcomes with Forxiga in the largest cardiovascular outcomes study to date. This data expanded the understanding of the benefits this class of medications can have in improving outcomes for patients, especially those patients at lower risk or no established cardiovascular disease.

In March 2019, following the read out of two phase 3 trials, Forxiga became the first licensed adjunct therapy to insulin for adult patients with type 1 diabetes.

Most recently, Forxiga is the first SGLT-2 to have been able to demonstrate cardiovascular benefits in a group of patients both with and without T2D. These exciting new findings offer clinically meaningful insights into the potential of the medicine to reduce the burden of heart failure in patients with and without type 2 diabetes.

Diabetes Times Special Achievement Award
WINNER: Napp Pharmaceuticals

Napp Pharmaceuticals is a privately owned UK company with a strong track record in bringing high quality, innovative medicines to UK health professionals and their patients.

Napp Pharmaceuticals believe in excellence and delivering on their promise to the NHS, patients, our business partners and each other. We strive to offer new medicines and initiatives that meet genuine needs, make a positive difference to patients’ lives and support the NHS in delivering effective, high-quality, sustainable healthcare.

TREND-UK Excellence in Nursing Education Award
WINNER: MSD

MSD is one of the top five biopharmaceutical companies in the UK and employ more than 2,000 people across five sites. For over 80 years, MSD has been researching, developing and supplying new medicines and vaccines that prevent and treat diseases that occur at every stage of life. As a global company, for over 125 years MSD has been guided by the conviction that great medicines change the world.

HIGHLY COMMENDED: Napp Pharmaceuticals

Working in partnership with highly respected UK education providers, such as Education for Health and Practice Nurse. The Napp Academy provides free, independently written CPD training, events and learning materials in the therapy areas of type 2 diabetes and asthma.

Napp Academy aims to provide high quality training and educational resources to healthcare professionals, supporting them in delivering the best possible care for their patients. 

Through meticulous planning, highly innovative and advanced research insights to truly understand customer needs and best practice website execution, Nappacademy.co.uk delivers a leading example of a non-promotional, online educational resource that delivers on all levels.

Whether it be independently written CPD training, expert opinion on the latest treatment advances, opportunities to complete accredited training courses or practical clinical guideline summaries, Nappacademy.co.uk has it all.

Leave a Reply